CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Down 54.0% in February

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) saw a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 6,400 shares, a drop of 54.0% from the January 31st total of 13,900 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 10,000 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Trading of CollPlant Biotechnologies

Institutional investors and hedge funds have recently modified their holdings of the business. Villere ST Denis J & Co. LLC raised its position in shares of CollPlant Biotechnologies by 24.4% during the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares during the last quarter. Benjamin Edwards Inc. acquired a new position in shares of CollPlant Biotechnologies in the third quarter worth $112,000. AMH Equity Ltd lifted its position in shares of CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after acquiring an additional 17,295 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of CollPlant Biotechnologies by 110.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after acquiring an additional 4,405 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of CollPlant Biotechnologies during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 21.69% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CLGN. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Friday, November 29th. D. Boral Capital reissued a “buy” rating and set a $14.00 price objective on shares of CollPlant Biotechnologies in a report on Wednesday, February 12th.

CollPlant Biotechnologies Stock Performance

Shares of CLGN stock opened at $3.50 on Friday. The stock has a fifty day moving average price of $3.77 and a 200 day moving average price of $4.21. The stock has a market cap of $40.09 million, a PE ratio of -2.27 and a beta of 0.86. CollPlant Biotechnologies has a 1 year low of $3.20 and a 1 year high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same quarter in the previous year, the business earned ($0.38) earnings per share. As a group, equities research analysts predict that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.